Business
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has received both public and private Human Research Ethics Committee (HREC) approvals in Australia for a Phase 1/2 clinical trial evaluating CYWC628 for the Tre
About this update from Fibrobiologics, Inc.
[{"type":"image","alt":"FibroBiologics, Inc.","displaySize":"","headline":null,"caption":"FibroBiologics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":77,"url":"https://media.zenfs.com/en/globenewswire.com/ea452943381e269d15ec4a2f87674425"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xw_QEbMhw7ViThavcOHCOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ea452943381e269d15ec4a2f87674425","width":300,"height":77}},"lazy":false},{"type":"text","content":"HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has received both public and private Human Research Ethics Committee (HREC) approvals in Australia for a Phase 1/2 clinical trial evaluating CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers (DFU). This approval enables enrollment of 120 patients at 10 sites across Australia. With the HREC approval and Therapeutics Goods Administration (TGA) filing now complete, FibroBiologics has secured all necessary regulatory approvals and submitted all required filings to proceed with the clinical trial.","length":848,"tagName":"p"},{"type":"text","content":"Southern Star Research, a leading full-service Australian CRO with APAC coverage, will manage all aspects of the CYWC628 trial from start to finish. “We are honored to continue our partnership with FibroBiologics whose leadership in cell therapy and regenerative medicine truly inspires us.” said Lloyd Prescott, CEO of Southern Star Research.","length":343,"tagName":"p"},{"type":"text","content":"The approved clinical trial is a prospective, multicenter, randomized study designed to evaluate the safety, tolerability, and efficacy of FibroBiologics’ investigational topically administered allogeneic fibroblast cell-based therapy, CYWC628, for the treatment of refractory DFU. Participants will receive up to 12 weeks of treatment using either standard of care (SoC) plus a low or high dose of CYWC628, or SoC alone.","length":421,"tagName":"p"},{"type":"text","content":"The trial will assess wound healing outcomes, efficacy of re...